European journal of clinical pharmacology · 2026
The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdel-Qader Derar H, Abdelsattar Nada K, Albassam Abdullah, Al-Kubais Khalid Awad, Taybeh Esra', Al Mazrouei Nadia, Ibrahim Rana, Ibrahim Osama Mohamed, Taha Taha Abd-ElSalam Ashraf
Аннотация
OBJECTIVE: This review aimed to assess the efficacy and safety of letrozole, administered either as monotherapy or combined with methotrexate, for the treatment of ectopic pregnancy (EP).
METHODS: Following established guidelines (PRISMA), a systematic review and meta-analysis was conducted. Major online research databases (Web of Science, PubMed, Scopus, and Cochrane Library) were searched for studies comparing letrozole to methotrexate in women diagnosed with EP via ultrasound, from the earliest available records up to November 5, 2024. The combined results were analyzed using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). The quality of the included studies was evaluated using ROB-2 and ROBINS-I tools.
RESULTS: Eight studies (five randomized and three non-randomized trials) involving 548 participants were included. Letrozole monotherapy achieved a higher treatment success rate compared to methotrexate (6 studies, 376 patients, RR 1.10, 95% CI [1.01, 1.20], p = 0.03). Combining letrozole with methotrexate showed comparable success rates to methotrexate alone (2 studies, 161 patients, RR 1.09, 95% CI [0.96, 1.23], p = 0.17). On day 4, β-human chorionic gonadotropin (β-hCG) levels decreased faster in both the letrozole monotherapy (5 studies, 291 patients, MD -131.15 mIU/mL, 95% CI [-220.77, -41.52], p = 0.004) and combination groups (2 studies, 136 patients, MD -188.79 mIU/mL, 95% CI [-242.07, -135.52], p < 0.00001). Letrozole monotherapy resulted in a smaller reduction in platelet count (2 studies, 76 patients, MD 81.61 × 10³/µL, 95% CI [40.11, 123.10], p = 0.0001) and better-preserved liver enzymes, such as ALT (3 studies, 76 patients, MD -21.27 IU/L, 95% CI [-24.42, -18.12], p < 0.00001). No differences were noted in anti-Müllerian hormone (AMH) levels (2 studies, 39 patients, MD -0.01 ng/mL, 95% CI [-0.40, 0.38], p = 0.97).
CONCLUSIONS: Letrozole, especially when used as the only treatment, may be a more effective and potentially safer alternative to methotrexate for medically treating EP. However, larger, higher-quality research studies are necessary to confirm these findings and to determine the best way to use letrozole.
METHODS: Following established guidelines (PRISMA), a systematic review and meta-analysis was conducted. Major online research databases (Web of Science, PubMed, Scopus, and Cochrane Library) were searched for studies comparing letrozole to methotrexate in women diagnosed with EP via ultrasound, from the earliest available records up to November 5, 2024. The combined results were analyzed using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). The quality of the included studies was evaluated using ROB-2 and ROBINS-I tools.
RESULTS: Eight studies (five randomized and three non-randomized trials) involving 548 participants were included. Letrozole monotherapy achieved a higher treatment success rate compared to methotrexate (6 studies, 376 patients, RR 1.10, 95% CI [1.01, 1.20], p = 0.03). Combining letrozole with methotrexate showed comparable success rates to methotrexate alone (2 studies, 161 patients, RR 1.09, 95% CI [0.96, 1.23], p = 0.17). On day 4, β-human chorionic gonadotropin (β-hCG) levels decreased faster in both the letrozole monotherapy (5 studies, 291 patients, MD -131.15 mIU/mL, 95% CI [-220.77, -41.52], p = 0.004) and combination groups (2 studies, 136 patients, MD -188.79 mIU/mL, 95% CI [-242.07, -135.52], p < 0.00001). Letrozole monotherapy resulted in a smaller reduction in platelet count (2 studies, 76 patients, MD 81.61 × 10³/µL, 95% CI [40.11, 123.10], p = 0.0001) and better-preserved liver enzymes, such as ALT (3 studies, 76 patients, MD -21.27 IU/L, 95% CI [-24.42, -18.12], p < 0.00001). No differences were noted in anti-Müllerian hormone (AMH) levels (2 studies, 39 patients, MD -0.01 ng/mL, 95% CI [-0.40, 0.38], p = 0.97).
CONCLUSIONS: Letrozole, especially when used as the only treatment, may be a more effective and potentially safer alternative to methotrexate for medically treating EP. However, larger, higher-quality research studies are necessary to confirm these findings and to determine the best way to use letrozole.